Oruka Therapeutics Inc. Common Stock (ORKA)

About ORKA

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phas…

Sector

Health Care

Industry

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Employees

68

Website

orukatx.com/

Fundamentals

1-day range

$91.01$95.45

Market cap

$5.72B

P/E (trailing)

—

P/E (forward)

-32.17

EPS (trailing)

$-2.39

Dividend yield

—

Beta

-0.43

Avg. volume

1.22M

Dividend pay date

August 28, 2024

Forecasts

12 analyst ratings

Oruka Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• ORKA

  Oruka Therapeutics Inc. Common Stock

  $91.07

  ▼ 5.67%
  Market cap $5.72BP/E —
  $14.61$115.52
• NEOG

  Neogen Corporation Common Stock

  $11.67

  ▼ 0.60%
  Market cap $2.59BP/E —
  $4.9$12.85
• NNNN

  Anbio Biotechnology Class A Ordinary Shares

  $7.64

  ▼ 1.80%
  Market cap $1.53BP/E 144.72
  $6.61$51.33
• NTLA

  Intellia Therapeutics Inc. Common Stock

  $12.87

  ▼ 1.83%
  Market cap $1.50BP/E —
  $7.95$28.25
• ACHV

  Achieve Life Sciences Inc. Common Shares

  $8.09

  ▼ 1.16%
  Market cap $648.81MP/E —
  $2.62$8.61
• TKNO

  Alpha Teknova Inc. Common Stock

  $7.13

  ▼ 2.46%
  Market cap $284.15MP/E —
  $1.91$7.84
• IMDX

  Insight Molecular Diagnostics Inc. Common Stock

  $4.16

  ▼ 3.03%
  Market cap $162.42MP/E —
  $2.33$8.51

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Oruka Therapeutics Files Prospectus For Offering $1B Mixed Shelf
  benzinga · 8/21/2026

Institutional Ownership

March 31, 2026

Total shares held

51.37M

Total value held

$2.48B

Institutional holders

178